Alethia Young
Stock Analyst at Cantor Fitzgerald
(3.68)
# 729
Out of 4,893 analysts
141
Total ratings
54.46%
Success rate
30.69%
Average return
Main Sectors:
Stocks Rated by Alethia Young
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCUS Arcus Biosciences | Reiterates: Overweight | n/a | $9.33 | - | 5 | Jul 5, 2024 | |
| ARWR Arrowhead Pharmaceuticals | Reiterates: Overweight | n/a | $18.88 | - | 5 | Jun 20, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $800 → $850 | $552.58 | +53.82% | 9 | Oct 16, 2023 | |
| ALXO ALX Oncology Holdings | Reiterates: Overweight | $18 | $0.50 | +3,497.84% | 6 | Sep 12, 2023 | |
| CRIS Curis | Reiterates: Overweight | $60 | $1.83 | +3,178.69% | 3 | Sep 7, 2023 | |
| ELDN Eledon Pharmaceuticals | Reiterates: Overweight | $9 | $3.40 | +164.71% | 2 | Aug 22, 2023 | |
| VSTM Verastem | Reiterates: Overweight | $34 | $4.81 | +606.86% | 2 | Jul 6, 2023 | |
| BIIB Biogen | Maintains: Neutral | $427 → $327 | $133.02 | +145.83% | 7 | Oct 15, 2021 | |
| ADVM Adverum Biotechnologies | Downgrades: Neutral | $230 → $30 | $2.55 | +1,076.47% | 4 | Jul 23, 2021 | |
| RAPT RAPT Therapeutics | Maintains: Overweight | $408 → $568 | $8.44 | +6,629.86% | 2 | Jun 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $285 → $281 | $478.97 | -41.33% | 5 | Jun 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $8 | $3.99 | +100.50% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $86 → $98 | $1.15 | +8,421.74% | 3 | Feb 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $280 → $295 | $296.52 | -0.51% | 9 | Feb 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $84 → $86 | $113.24 | -24.06% | 3 | Oct 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $48 | $37.92 | +26.58% | 4 | Oct 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $8.00 | +275.00% | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $72 | $39.07 | +84.28% | 8 | Jul 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $5 | $1.48 | +237.84% | 5 | Jun 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $83 → $100 | $68.72 | +45.52% | 6 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $185 → $201 | $175.57 | +14.48% | 6 | Apr 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $86 → $85 | $48.74 | +74.39% | 5 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $32 | $8.39 | +281.41% | 1 | Mar 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $211 → $217 | $19.37 | +1,020.29% | 12 | Feb 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $75 → $48 | $25.74 | +86.48% | 4 | Oct 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $10.51 | - | 3 | Mar 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $151 → $154 | $320.87 | -52.01% | 5 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $113 → $116 | $59.67 | +94.40% | 2 | Mar 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $147 → $106 | $3.60 | +2,844.44% | 8 | Jan 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $28 | $12.13 | +130.83% | 1 | Nov 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $85 → $82 | $215.83 | -62.01% | 2 | Sep 27, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | n/a | $300.56 | - | 1 | Mar 16, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.08 | - | 1 | Oct 18, 2016 |
Arcus Biosciences
Jul 5, 2024
Reiterates: Overweight
Price Target: n/a
Current: $9.33
Upside: -
Arrowhead Pharmaceuticals
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $18.88
Upside: -
Regeneron Pharmaceuticals
Oct 16, 2023
Maintains: Neutral
Price Target: $800 → $850
Current: $552.58
Upside: +53.82%
ALX Oncology Holdings
Sep 12, 2023
Reiterates: Overweight
Price Target: $18
Current: $0.50
Upside: +3,497.84%
Curis
Sep 7, 2023
Reiterates: Overweight
Price Target: $60
Current: $1.83
Upside: +3,178.69%
Eledon Pharmaceuticals
Aug 22, 2023
Reiterates: Overweight
Price Target: $9
Current: $3.40
Upside: +164.71%
Verastem
Jul 6, 2023
Reiterates: Overweight
Price Target: $34
Current: $4.81
Upside: +606.86%
Biogen
Oct 15, 2021
Maintains: Neutral
Price Target: $427 → $327
Current: $133.02
Upside: +145.83%
Adverum Biotechnologies
Jul 23, 2021
Downgrades: Neutral
Price Target: $230 → $30
Current: $2.55
Upside: +1,076.47%
RAPT Therapeutics
Jun 14, 2021
Maintains: Overweight
Price Target: $408 → $568
Current: $8.44
Upside: +6,629.86%
Jun 11, 2021
Maintains: Overweight
Price Target: $285 → $281
Current: $478.97
Upside: -41.33%
Mar 8, 2021
Initiates: Overweight
Price Target: $8
Current: $3.99
Upside: +100.50%
Feb 25, 2021
Maintains: Overweight
Price Target: $86 → $98
Current: $1.15
Upside: +8,421.74%
Feb 3, 2021
Maintains: Overweight
Price Target: $280 → $295
Current: $296.52
Upside: -0.51%
Oct 29, 2020
Reiterates: Overweight
Price Target: $84 → $86
Current: $113.24
Upside: -24.06%
Oct 28, 2020
Maintains: Overweight
Price Target: $30 → $48
Current: $37.92
Upside: +26.58%
Oct 12, 2020
Initiates: Overweight
Price Target: $30
Current: $8.00
Upside: +275.00%
Jul 31, 2020
Maintains: Overweight
Price Target: $70 → $72
Current: $39.07
Upside: +84.28%
Jun 2, 2020
Assumes: Overweight
Price Target: $5
Current: $1.48
Upside: +237.84%
May 19, 2020
Maintains: Neutral
Price Target: $83 → $100
Current: $68.72
Upside: +45.52%
Apr 20, 2020
Reiterates: Overweight
Price Target: $185 → $201
Current: $175.57
Upside: +14.48%
Apr 8, 2020
Reiterates: Overweight
Price Target: $86 → $85
Current: $48.74
Upside: +74.39%
Mar 6, 2020
Maintains: Overweight
Price Target: $30 → $32
Current: $8.39
Upside: +281.41%
Feb 27, 2020
Reiterates: Overweight
Price Target: $211 → $217
Current: $19.37
Upside: +1,020.29%
Oct 3, 2019
Maintains: Neutral
Price Target: $75 → $48
Current: $25.74
Upside: +86.48%
Mar 22, 2018
Downgrades: Underperform
Price Target: n/a
Current: $10.51
Upside: -
Mar 13, 2018
Maintains: Outperform
Price Target: $151 → $154
Current: $320.87
Upside: -52.01%
Mar 2, 2018
Maintains: Outperform
Price Target: $113 → $116
Current: $59.67
Upside: +94.40%
Jan 24, 2018
Maintains: Outperform
Price Target: $147 → $106
Current: $3.60
Upside: +2,844.44%
Nov 3, 2017
Maintains: Outperform
Price Target: $24 → $28
Current: $12.13
Upside: +130.83%
Sep 27, 2017
Maintains: Neutral
Price Target: $85 → $82
Current: $215.83
Upside: -62.01%
Mar 16, 2017
Initiates: Underperform
Price Target: n/a
Current: $300.56
Upside: -
Oct 18, 2016
Initiates: Outperform
Price Target: n/a
Current: $2.08
Upside: -